VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

Ad5-nCoV Vaccine
Vaccine Information
  • Vaccine Name: Ad5-nCoV Vaccine
  • Target Pathogen: SARS-CoV-2
  • Target Disease: COVID-19
  • Vaccine Ontology ID: VO_0005144
  • Type: Recombinant vector vaccine
  • Status: Clinical trial
  • Host Species for Licensed Use: Human
  • Antigen: SARS-CoV-2 spike protein (Zhu et al., 2020)
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Human Response

  • Vaccination Protocol: Patients were immunized with 5 × 10e10 viral particles per 0·5 mL (low dose), 1 × 10e11 viral particles per mL (middle dose), or 1.5 × 10e11 viral particles per 1·5 mL (high dose). (Zhu et al., 2020)
  • Immune Response: Anti-RBD antibodies detected at day 14. NAb titers peaked at day 28. TNF-α levels from CD8+ cells were highest in the high dose group. IFN-γ, IL-2 and TNF-α were detected in all groups. (Zhu et al., 2020)
References
Zhu et al., 2020: Zhu FC, Li YH, Guan XH, Hou LH, Wang WJ, Li JX, Wu SP, Wang BS, Wang Z, Wang L, Jia SY, Jiang HD, Wang L, Jiang T, Hu Y, Gou JB, Xu SB, Xu JJ, Wang XW, Wang W, Chen W. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet (London, England). 2020; 395(10240); 1845-1854. [PubMed: 32450106].